Description

Sermorelin Acetate (RUO) | GHRH 1-29 Agonist | ≥99% Purity

Prodcut Specification

• Product Name : Sermorelin Acetate (Research Grade)
• CAS Number : 86168-78-7
• Synonyms / Common Names : Sermorelin acetate hydrate 114466-38-5 AKOS040744848
• Molecular Formula : C151H252N44O45S
• Molecular Weight : 3436.0 g/mol
• Peptide Type : Growth Hormone-Releasing Hormone (GHRH) Agonist
• Target Receptor : GHRH Receptor (GHRHR)
• Purity : ≥99% (HPLC Verified)
• Form : Lyophilized White Powder
• Solubility : Soluble in bacteriostatic water or sterile water
• Endotoxin Level : Less than 1.0 EU/mg

Disclaimer : For Research Use Only (RUO). Not for human use.

Chemical Identity & “Survivor” Status

Sermorelin (GRF 1-29) is a synthetic polypeptide comprising the first 29 amino acids of endogenous human GHRH. Unlike newer synthetic peptides that have faced regulatory bans, it possesses a unique “Safe Harbor” status in the USA.

Structural Efficiency : It contains the full biological activity of GHRH within the N-terminal 29-amino acid sequence, making it highly specific to the GHRH receptor.

Regulatory Resilience : Because it is the active ingredient of a formerly FDA-approved drug (Geref) that was not withdrawn for safety reasons, it remains the “Last Peptide Standing” for compliant research into the somatotropic axis.

Preservation of Physiology : Unlike exogenous hormones, It stimulates the anterior pituitary to secrete growth hormone in a pulsatile manner.

Chemical structure of Sermorelin Acetate (GRF 1-29)

Verified 2D chemical structure of Sermorelin Acetate (GHRH 1-29) peptide (CAS 86168-78-7) showing the biologically active N-terminal fragment for pituitary research.

This synthetic 29-amino acid peptide retains the full biological activity of endogenous GHRH, optimized as an acetate salt for stability and solubility in research protocols.

 

The Physiological Advantage: Sermorelin vs. rhGH vs. Reta

 

It is distinct because it works with the body’s natural feedback loops, specifically the inhibitory control of somatostatin.

 

Research Context & Clinical Insights (2025-2026)

 

Parameter	Sermorelin (GHRH)	rhGH (Synthetic)	Reta / Tirz (Incretins)
Mechanism	Stimulates Endogenous GH	Replaces Natural GH	GLP-1 / GIP Agonism
Release Pattern	Pulsatile (Natural Spikes)	“Square Wave” (Continuous)	Constant Exposure
Feedback Loop	Preserved (Safe)	Bypassed (Suppressive)	N/A (Metabolic Focus)
Primary Research	Sleep (SWS) + Recovery	Height / Growth Failure	Weight Loss / Diabetes
Safety Profile	Self-Limiting (No Overdose)	Risk of Acromegaly/Edema	GI Distress

 

Sleep Architecture (Deep Sleep)

 

Research indicates it acts as a neurotransmitter to promote Slow-Wave Sleep (SWS), the restorative stage where endogenous recovery peaks. This makes it a critical tool for studying age-related sleep decline.

 

Body Composition & Visceral Fat : By restoring GH pulsatility, Sermorelin reactivates lipolytic machinery in visceral fat depots. Studies in aging models showed increases in lean body mass (+1.4 kg in men) and improvements in skin thickness (collagen density)

 

The “Stacking” Shift : With Ipamorelin now placed in FDA Category 2 (restricted), researchers are shifting focus to Sermorelin Monotherapy. It remains the primary legal tool for stimulating the somatotropic axis in the USA.

 

Why Researchers Source Sermorelin from Profound Aminos

 

The “Grey Market” Antidote: While many vendors sell undefined “research chemicals,” our Sermorelin is strictly tested to confirm it is NOT a salt-heavy synthesis byproduct. We ensure <1.0 EU/mg endotoxin levels for safe cellular assays.

 

USA-Based Cold-Chain: Peptides are fragile. We store our inventory at -20°C in the USA to prevent degradation of the amino acid sequence before it reaches your lab.

 

Verified Sequence: COA confirms the 1-29 fragment identity, ensuring you are researching the specific biologically active motif.

 

Regulatory & Compliance Statement

 

Classification : Research Use Only (RUO) Peptide.

 

Compliance: Sermorelin acetate is listed as a compliant bulk drug substance for 503A compounding under the FD&C Act, as the API of a formerly approved drug (Geref).

 

Usage: Strictly for Laboratory Research Use Only. Not for human consumption, diagnostic, or clinical procedures.

 

Frequently Asked Questions

 

Q: Why is Sermorelin considered the “Safest” GHRH analogue for research?

 

A: Unlike rhGH, which can cause overdose and shutdown of the pituitary gland, it is self-limiting. It remains subject to the body’s Somatostatin negative feedback loop. If GH levels get too high, the body naturally blocks the effect of Sermorelin, making overdose virtually impossible in research models

 

Q: How does Sermorelin compare to “trending” peptides like Reta or Sema?

 

A: They target completely different systems. Reta and Sema are incretin mimetics focused on insulin sensitivity and appetite suppression for obesity/T2D. It focuses on the Neuroendocrine Axis—specifically repairing the pulsatile secretion of Growth Hormone for tissue repair, sleep optimization, and anti-aging modeling.

 

Q: Why is this peptide preferred over Ipamorelin in 2026?

 

A: Regulatory necessity. In late 2023/2024, the FDA moved Ipamorelin to Category 2, effectively restricting its compliant compounding use37. Sermorelin was not restricted because it was previously an FDA-approved drug (Geref) with a proven safety record, making it the “Gold Standard” for legally compliant research.

 

Q: Does Sermorelin show immediate effects in metabolic studies?

 

A: Unlike the rapid weight loss seen with Tirz, Sermorelin’s effects are cumulative. Research shows significant elevation of IGF-1 levels typically occurs within 4 to 12 weeks of nightly administration in study protocols.